Dennis J. Selkoe, MD, professor of neurology at Brigham and Women’s Hospital; Michael G. Erkkinen, MD, cognitive behavioral neurologist at Brigham and Women’s Hospital; and Lawren VandeVrede, MD, PhD, assistant professor at University of California, San Francisco, discuss eligibility for anti-amyloid treatment for mild cognitive impairment and dementia with confirmed amyloid pathology.

Dennis J. Selkoe, MD, professor of neurology at Brigham and Women’s Hospital; Michael G. Erkkinen, MD, cognitive behavioral neurologist at Brigham and Women’s Hospital; and Lawren VandeVrede, MD, PhD, assistant professor at University of California, San Francisco, discuss eligibility for anti-amyloid treatment for mild cognitive impairment and dementia with confirmed amyloid pathology.

Dennis J. Selkoe, MD, professor of neurology at Brigham and Women’s Hospital; Michael G. Erkkinen, MD, cognitive behavioral neurologist at Brigham and Women’s Hospital; and Lawren VandeVrede, MD, PhD, assistant professor at University of California, San Francisco, discuss eligibility for anti-amyloid treatment for mild cognitive impairment and dementia with confirmed amyloid pathology.

Fred Lublin, MD; Aaron Miller, MD; and Stephen Krieger, MD, all professors of neurology at the Icahn School of Medicine at Mount Sinai, New York City, New York, discuss real-world adherence and persistence to disease-modifying therapies in multiple sclerosis, including optimizing treatment selection and patient-centered solutions.

Fred Lublin, MD; Aaron Miller, MD; and Stephen Krieger, MD, all professors of neurology at the Icahn School of Medicine at Mount Sinai, New York City, New York, discuss real-world adherence and persistence to disease-modifying therapies in multiple sclerosis, including optimizing treatment selection and patient-centered solutions.

Fred Lublin, MD; Aaron Miller, MD; and Stephen Krieger, MD, all professors of neurology at the Icahn School of Medicine at Mount Sinai, New York City, New York, discuss real-world adherence and persistence to disease-modifying therapies in multiple sclerosis, including optimizing treatment selection and patient-centered solutions.